Volume 16 Supplement 2
Does ‘mapping’ the evidence usefully inform the research question prioritisation process in systematic reviews?
© Main et al. 2015
Published: 16 November 2015
Defining the research questions in systematic reviews is a very important first stage in the process, providing the framework for subsequent stages. With numerous questions and uncertainty regarding the strength and size of the evidence base for undertaking reviews on the effectiveness of interventions for children's central nervous system (CNS) tumours a ‘map’ of the evidence was produced.
Ten electronic databases were searched for published and on-going studies on surgical procedures, radiotherapy (RT), chemotherapy (CT), hormone therapy (HT), immunotherapy, biological therapies and imaging from 1985 to November 2014. No study design filters were applied. Studies were categorised as relevant interventions, or excluded due to the patient population or lack of relevant intervention. All included studies were then categorised by tumour histology type, intervention and study design on the basis of the available abstract.
A total of 8,448 references were identified; with 1,665 studies included in the ‘map’. Twelve systematic reviews, 30 randomised controlled trials (RCTs) and 200 single arm phase II trials with 8785 participants were identified. The majority of the evidence was limited to case series studies (1,076) or case reports with less than 5 patients (306). Chemotherapy regimens, either alone or in combination with RT were the most frequently assessed interventions. There were very few studies of HT, immunotherapy or biological agents identified.
‘Mapping’ where evidence is scarce or of a lower quality is a useful tool for prioritising research questions, re-defining initial conceptualisation of questions, highlighting gaps and prioritising review schedules when emerging technologies are being assessed.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.